A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne - Trial NCT06336629
Access comprehensive clinical trial information for NCT06336629 through Pure Global AI's free database. This Phase 4 trial is sponsored by Sun Pharmaceutical Industries Limited and is currently Recruitment Completed. The study focuses on Acne Vulgaris. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Pharmaceutical Industries Limited
Timeline & Enrollment
Phase 4
Nov 15, 2023
Oct 01, 2024
Primary Outcome
The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16.
Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris.
 There is no study assessing Winlevi in combination treatment for acne .Therefore this study
 assesses Winlevi with Duac gel in combination to emulate real life practice.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336629
Non-Device Trial